IonQ enters the post-earnings session on the back foot for short sellers. The quantum computing company delivered a Q1 print that beat on every line, then raised full-year guidance well above consensus — and shares are already up 64% over the past month heading into the reaction.
The numbers tell the story starkly. Q1 revenue came in at $64.7M, clearing the $49.7M analyst estimate by nearly 30%. Adjusted EPS of $(0.34) edged past the $(0.35) estimate. Management then raised FY2026 revenue guidance to $260M–$270M from the prior $225M–$245M range, against a Street estimate of $235.7M. Q2 guidance of $65M–$68M also topped the $54.9M consensus. For a stock already trading at speculative multiples, this is the kind of fundamental validation bulls have been waiting for.
The borrow market was already strained before those numbers crossed. Short interest has been entrenched near 23.3% of the free float for weeks, barely moving — it's climbed steadily from roughly 22.1% in late March. That persistence matters now. Availability is extremely tight, with utilization running at 96% and touching 100% just last week. Borrowing costs nearly tripled from below 1% in early April to a peak of nearly 3% in mid-April before settling back to 1.49%. With short interest this elevated and availability this constrained, any post-earnings cover attempt faces a structurally thin lending pool. The ORTEX short score of 71 — ranked in the bottom 2nd percentile of the universe on short-score rank — confirms the setup as one of the more pressured on the board.
The Street has been mixed but is gradually being dragged toward the bull camp. Wedbush reiterated Outperform with a $60 target just this week, and Northland Capital Markets initiated at Outperform with a $55 target on April 20. The divergence is wide: Rosenblatt carries a $100 target with a Buy, while JPMorgan and Morgan Stanley sit at Neutral with targets of $42 and $35 respectively — the latter looking increasingly stale against a stock now trading at $48. The mean price target of $63.91 implies roughly 33% upside from current levels, though that average is being skewed by the wide dispersion. Bulls point to the projected 80% FY26 revenue growth, a $3.3B cash and investments position, and IonQ's ion-trap technology differentiation. Bears flag 43x CY2026 revenue as a valuation that leaves little room for execution missteps, plus customer concentration risk and the still-pending SkyWater Technologies acquisition.
Options positioning has shifted notably more cautious over the past month. The put/call ratio of 0.99 is above its 20-day average of 0.91, having drifted higher from a 52-week low of 0.75 in mid-April when sentiment was more openly bullish. The z-score of 0.81 is not extreme, but the directional trend — PCR rising as the stock rallied — suggests options traders were hedging into the print rather than chasing calls.
Institutional ownership adds another layer of complexity. Vanguard and BlackRock together hold more than 17% of shares, with BlackRock adding 7.6M shares as of April 30. Insider activity has been one-directional: every recent transaction on record since February has been a sale, including the CEO selling ~$723K of stock at $34.80 on March 11. Insiders have net sold roughly 53,000 shares over the past 90 days. That's not dramatic in dollar terms, but the absence of any buying at these levels is worth noting as the stock approaches post-earnings highs.
The next confirmed catalyst is the Q2 earnings event on June 16. What to watch between now and then: whether short sellers begin covering meaningfully against a backdrop of near-zero availability, and whether the guidance raise prompts target-price upgrades that close the gap between the sceptics at JPMorgan and Morgan Stanley and the more optimistic end of the analyst range.
See the live data behind this article on ORTEX.
Open IONQ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
